Trials Sponsors Conditions Drugs Pricing

Conditions

Gestational Diabetes Postpartum

Keywords

Continuous Glucose MonitoringPostpartum Glucose Management

Outcome Measures

Primary Outcomes (5)

Mean Glucose
24-hour mean glucose based on Stelo Glucose Biosensor readings
Measured from birth to 6 weeks postpartum, and for 15 days at 3, 6, 9, and 12 months postpartum.
Glucose Percent Time in Range
Percent time-in-range (percent of the time between 70-140 mg/dL or 70-120 mg/dL) based on Stelo Glucose Biosensor readings
Measured from birth to 6 weeks postpartum, and for 15 days at 3, 6, 9, and 12 months postpartum.
Glucose Percent Time Above Range
Percent time-above-range (percent of the time above 140 mg/dL or 120 mg/dL) based on Stelo Glucose Biosensor readings
Measured from birth to 6 weeks postpartum, and for 15 days at 3, 6, 9, and 12 months postpartum.
Postpartum Fasting Glucose
Postpartum fasting glucose as determined by a blood test
Measured at 6 and 12 months postpartum
Postpartum A1C
Postpartum Hemoglobin A1C as determined by a blood test
Measured at 6 and 12 months postpartum

Study Arms (1)

Postpartum Stelo Users

Postpartum individuals with their most recent pregnancy complicated by Gestational Diabetes Mellitus (GDM)

Device: Dexcom Stelo real-time Continuous Glucose Monitor

Interventions

Dexcom Stelo real-time Continuous Glucose MonitorDevice

The Stelo Glucose Biosensor is an over-the-counter integrated Continuous Glucose Monitor (iCGM) intended to continuously measure, record, analyze, and display glucose values in people 18 years and older not on insulin. Participants will use Stelo for the 6 weeks following delivery and for 15 days at 3 months, 6 months, 9 months, and 1 year postpartum.

Postpartum Stelo Users

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexfemale

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Postpartum individuals with pregnancies complicated by GDM.

You may qualify if:

Gestational Diabetes Mellitus (GDM) diagnosis by 1- or 2-step Oral Glucose Tolerance Test (OGTT) during pregnancy or \>= 200 mg following any glucose challenge (50g, 75g, 100g)

Sponsors & Collaborators

Sansum Diabetes Research Institute
Othercollaborator
Oregon Health and Science University
Otherlead
DexCom, Inc.

Study Sites (3)

Sansum Diabetes Research Institute

Santa Barbara, California, 93105, United States

Alex AlChwikani, Recruitment SpecialistCONTACT805-682-7640 Aalchwikani@sansum.org

Kristin Castorino, DOPRINCIPAL INVESTIGATOR

Oregon Health & Science University

Portland, Oregon, 97239, United States

Christian Huertas PaganCONTACT503-418-1231 mfmresearch@ohsu.edu

Amy M Valent, DO, MCRPRINCIPAL INVESTIGATOR

MeSH Terms

Conditions

Diabetes, Gestational

Condition Hierarchy (Ancestors)

Pregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesDiabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Officials

Amy M Valent, DO, MCR
Oregon Health and Science University
PRINCIPAL INVESTIGATOR
Celeste Durnwald, MD
University of Pennsylvania
PRINCIPAL INVESTIGATOR
Kristin Castorino, DO
Sansum Diabetes Research Institute
PRINCIPAL INVESTIGATOR

Central Study Contacts

Christian Huertas Pagan

CONTACT

503-418-1231 mfmresearch@ohsu.edu

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Principal Investigator

Study Record Dates

First Submitted

January 12, 2026

First Posted

January 21, 2026

Study Start

January 2026

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Primary Completion

December 2027

Stelo Real-time Continuous Glucose Monitor Use Postpartum for Lifelong Optimal Wellness

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (5)

Study Arms (1)

Postpartum Stelo Users

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (3)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (5)

Study Arms (1)

Postpartum Stelo Users

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (3)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations